Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Investigational drugs: Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug
Patients who are currently receiving another investigational drug are not eligible
Subjects who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible.
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Investigational Drugs\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Prior treatment with another investigational drug
Patients who are currently receiving another investigational therapy are excluded
Patients who are currently receiving another investigational drug are not eligible
Patients receiving any other investigational drug therapy
Is currently receiving another investigational therapy
Patients who are currently receiving another investigational drug are NOT eligible for either Stratum
Patients currently receiving any other standard or investigational therapy for the treatment of AML
Must not be currently receiving any investigational drugs
Patients who are currently receiving another investigational drug are not eligible.
Patients who are currently receiving another investigational drug
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug
Patients who are currently receiving another investigational drug
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Not currently receiving other investigational drugs
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients who are currently receiving another investigational drug are not eligible
Patients currently receiving other investigational drugs are not eligible
Patients who are currently receiving another investigational drug are not eligible
Currently receiving any other investigational medication or therapy
Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.
Investigational Drugs: Patients who are currently receiving another investigational drug are excluded from participation.
Patients who are currently receiving another investigational therapy are excluded
Concurrent use of any other anti-cancer agents or treatments or any other investigational agents
Concurrent use of any other anti-cancer agents or treatments or any other investigational agents
Concurrent use of other anti-cancer agents or treatment
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments.
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or experimental treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or experimental treatments
Concurrent use of other anti-cancer agents or treatments.
Concurrent use of other anti-cancer agents or experimental treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or anti-cancer treatments
Concurrent use of any other anti-cancer treatments or any other investigational agents
Concurrent use of any other anti-cancer agents or treatments or any other study agents
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments.
Patient has concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Use of anti-cancer treatments within 28 days
Concurrent use of other anti-cancer agents or treatments, including other investigational agents
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of other anti-cancer agents or treatments
Concurrent use of any other anti-cancer agents or treatments or any other study agents
Concurrent use of other anti-cancer agents or treatments
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid \r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients must not be receiving any other investigational anti-cancer agents while on study
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A/CYP3A4 agents: patients who are currently receiving drugs that are strong and moderate inducers or inhibitors of CYP3A or CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 21 days prior to enrollment to the end of the study
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\r\n* CYP2C9 agents: patients who are currently receiving drugs that are moderate to strong inducers or inhibitor of CYP2C9 are not eligible\r\n* P-glycoprotein: patients who are currently receiving drugs that are potent inhibitors of p-glycoprotein are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study\r\n** Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Receiving any other investigational agents or any other anti-cancer therapy
Patients currently receiving investigational or commercial anti-cancer agents or anti-cancer therapies other than BCG, ALT-803 and supportive care therapies.
Subjects who are currently receiving any other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents or radiation therapy are not eligible.
Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy)
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving anti-platelet agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Anti-cancer Agents\r\n* Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Prior treatment with other anti-cancer agents
Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
Concomitant medications\r\n* Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anticonvulsants: Patients who are receiving enzyme-inducing anticonvulsants are not eligible\r\n* Anticoagulants: Use of warfarin is not allowed while on study; patients already on warfarin should use alternative anticoagulants while on this study; warfarin must not have been administered within 7 days of enrollment\r\n* Smoking: Patients must not smoke for 10 days prior to enrollment and for the duration of therapy
Patients who are currently receiving other anti-cancer agents are not eligible
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Concomitant medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; corticosteroids must be held for 24 hours prior to initiation of study therapy\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible; the definition of “investigational” for use in this protocol means any drug that is not licensed by the Food and Drug Administration (FDA)\r\n* Anti-cancer agents: Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible (except leukemia patients who relapsed on maintenance therapy or patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); intrathecal therapy may be given up to one week prior to initiation of study treatment\r\n* Anti-graft versus host disease (GVHD) or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial; at least 3 half-lives must have elapsed after the last dose of GVHD meds\r\n* Angiotensin-converting enzyme (ACE) inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with everolimus + ACE inhibitors; at least 3 half-lives must have elapsed after the last dose of ACE inhibitors\r\n* Anti-convulsants: Patients who are currently receiving CYP3A4/PgP enzyme inducing anticonvulsants (eg. phenytoin, phenobarbitol, or carbamazepine) are not eligible; stabilizing on a non-hepatic inducing metabolizing anti-convulsant (ie: gabapentin or levetiracetam) prior to study entry is acceptable; at least 3 half-lives must have elapsed after the last dose of enzyme inducing anti-convulsants\r\n* Inhibitors of everolimus metabolism: Patients receiving treatment with azoles such as fluconazole or voriconazole which are potent inhibitors of everolimus metabolism; at least 3 half-lives must have elapsed after the last dose of azoles
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving any other anti-neoplastic agents
Concomitant Medications\r\n* Corticosteroids: Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible\r\n* Investigational drugs: Patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: Patients who are currently receiving other anti-cancer agents are not eligible\r\n* CYP3A4 active agents: Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors (erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John’s wort)\r\n* Patients who are receiving systemic therapeutic treatment anticoagulation are not eligible; patients receiving prophylactic systemic anticoagulation will be allowed with heparin or low-molecular-weight heparin (LMWH) as long as eligibility PT/INR requirements are met; concomitant anticoagulation with oral anticoagulations (e.g. warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (eg. clopidogrel) are not allowed\r\n* Enzyme-inducing anticonvulsants: Patients must not have received enzyme–inducing anticonvulsants within 14 days prior to enrollment \r\n* QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible
Patients who are currently receiving other anti-cancer/devices agents are NOT eligible for either Stratum
Patients may not be receiving any other investigational and/or anti-cancer agents
Concomitant medications\r\n* Corticosteroids: patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\r\n* Investigational drugs: patients who are currently receiving another investigational drug are not eligible\r\n* Anti-cancer agents: patients who are currently receiving other anti-cancer agents are not eligible\r\n* Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial\r\n* CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study\r\n* CYP2C19 agents: patients who are currently receiving drugs that are strong CYP2C19 inducers (e.g., rifampin, ritonavir) or inhibitors (e.g.., fluoxetine, fluvoxamine, ticlopidine) are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible.
Patient is NOT receiving any other anti-cancer agents or radiotherapy at the time of study entry
Patients must NOT receive other anti-cancer agents while on study
Patients must not be currently receiving other anti-cancer agents
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
Patients who are currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving or plan to receive other anti-cancer agents (except hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy and intrathecal chemotherapy)
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study
Patients who are currently receiving other anti-cancer agents with the exception of those delineated in the eligibility criteria
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents are not eligible (except leukemia patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy); patients with acute lymphoblastic leukemia may receive intrathecal therapy
Patients who are currently receiving other anti-cancer agents are not eligible
Patients who are currently receiving other anti-cancer agents, with the exception of hydroxyurea for patients with ALCL, are not eligible
Anti-neoplastic agents
Patients who are currently receiving other anticancer agents are not eligible
Patients receiving any other investigational agents or any additional anti-cancer agents
Patients may not be receiving any other investigational agents; patients cannot be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy for the purposes of anti-cancer treatment
Patients receiving other anti-neoplastic agents are excluded
Concomitant medications\r\n* Patients receiving stable or decreasing corticosteroids are not eligible for other concurrent conditions (e.g. asthma, autoimmune diseases, rash, documented adrenal insufficiency) are eligible for this study\r\n* Patients who are currently receiving another investigational drug are not eligible\r\n* Patients who are currently receiving other anti-cancer agents are not eligible
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Currently receiving other anti-cancer agents
Patients who are currently receiving other anti-cancer agents are excluded from this trial
Patients receiving any other investigational anti-cancer agents
Patients who are currently receiving other anti-cancer agents are not eligible
Receiving any other investigational agents or any other anti-cancer therapy
Patients may not be receiving any other investigational agents or active anti-neoplastic therapies
Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.
Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).
Treatment with any anti-cancer agents within 28 days of study entry
Treatment with any anti-cancer agents within 28 days of study entry
Patients who are currently receiving other anti-cancer agents are not eligible except for hydroxyurea (which may be continued until 24 hours prior to start of protocol therapy)
All cancer patients receiving chemotherapy agents
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from hematological and bone marrow suppression effects of prior chemotherapy.
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (hematological and bone marrow suppression effects).
Anti-cancer Agents: Patients who are currently receiving other anticancer agents are not eligible. Patients must have fully recovered from the effects of prior chemotherapy, generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas).
Patients must not currently be using other anti-cancer agent
Anti-cancer agents: must not be receiving other anti-cancer agents at time of enrollment and must not be planning to take other anti-cancer agents during DLT period
Eligible Ages in Australia and Canada; 2 years to 21 years
Chemotherapy within 5 years prior to registration; (hormonal therapy is allowable if the disease free interval is >= 5 years)
Adult patients ? 18 years
Subjects with leptomeningial disease or neoplasms in the last 5 years
Patients must fit into one of the following categories:\r\n* Age >= 18 years to < 60 years with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator\r\n* >= 60 years
Be between the ages of ?18 and ?65 years
St. Jude patients must be between 2 years and =< 21 years of age, on therapy (active patient), or within 3 years of completion of therapy; patients treated at collaborating sites must be =< 24 years old
Prior chemotherapy within the last 2 years
Prior chemotherapy for any other cancer within the last 2 years
Other known active cancer(s) likely to require treatment in the next two (2) years
Diagnosed with SMM within the last 4 years
Other known active cancer(s) likely to require treatment in the next two (2) years
< 30% for patients < 60 years,
Patient must be > 18 years
Less than or equal to 10 pack years of tobacco history
Prior systemic chemotherapy within the last three years
Be between the ages of ?18 and ?65 years
Prior chemotherapy within 5 years.
within the last 5 years OR
>18 years
History of other cancer within 3 years
Predicted time to first treatment of ?3 years according to MDACC nomogram.
History of metastatic cancer diagnosed less than 2 years prior to the first planned dose of PF-0444913
Diagnosis < 3 years prior to entry
Diagnosed less than 3 years prior to entry on trial
Cohort 4 only: ?10 years to ?21 years
History of other cancer within 3 years.
Subjects who have had any prior chemotherapy within 5 years of enrollment
Patients with a history of pituitary irradiation can be included, provided that at least 2 years (stereotactic radiosurgery) or 3 years (conventional radiation) have elapsed from the time of last radiation treatment to the time of enrollment into this study.
Have undergone treatment with systemic chemotherapy within the last 1-5 years
Patient has been on TKI therapy for at least 3 years
Patients who received chemotherapy > 5 years ago for malignancies other than pancreatic cancer are eligible, provided that chemotherapy was completed > 5 years ago and that there is no evidence of the second malignancy at the time of study entry
Life expectancy > 10 years based on clinician’s judgment
Prior chemotherapy treatment unless =< 5 years ago
At NIH: age >= 15 years old and/or >= 9 years old and pubertal and =< 55 years for recipient; pubertal is defined by: prior menses at any time (females), documentation of clinical Tanner stage greater than 2 at some point pre-chemotherapy or at the current visit; (at this point, sex steroids have been produced for a few years which has driven initial pubertal development); Tanner 2 is defined as: breast buds for females with coarse pubic hair, and coarse pubic hair and testes > 2.5 cm for males
Prior treatment with IL2 within the last 5 years
?18 years.
Ages 50-70 years,
PATIENT: >= 65 years
Within 2 years post-treatment completion for lymphoma
Ages 25-65 years
Patients that are between 1-5 years post treatment
Currently between 1.0-4.99 years from the completion of active cancer therapy
Willingness to be followed for the planned duration of the trial (2 years)
Off treatment > 14 years
Time from completion of cancer treatment to study entry: >= 2 years
For dose-escalation stage (tablets): age at study entry >= 6 years to < 18 years
Completion of two years monthly zoledronic acid therapy
Prior mammogram (if any) more than 3 years ago
No Pap test in the last 3 years
Report not having had a pap smear in the last three years
Received colposcopy of cervix within TWO years
Plans to relocate from the area within one years
Driver for at least 3 years
Have smoked for at least 3 years;
At time of approach, >= 5 years from initial cancer diagnosis or >= 5 years from first HCT, whichever is later.
Adult (?18 years)
History of invasive carcinoma =< 5 years (except subjects with Dukes A/B1 carcinoma =< 5 years prior to pre-registration or any stage of colon cancer if >= 3 years post surgical resection)
Between 1-5 years post completion of chemotherapy
Colonoscopy within the last three years that found >= 1 adenoma
Diagnosed alcoholism within the last 5 years
Disease duration 10 years or less (RCT)
Due for CRC screening:\r\n* No colonoscopy within the prior 10 years\r\n* No flexible sigmoidoscopy within the prior 5 years\r\n* No fecal blood testing (FOBT or FIT) within the prior 12 months
Off of all cancer therapy for >= 2 years
Patients younger than 18 years
?18 years
Must not have received investigational therapy within 30 days of entry onto this study
Treatment with radiation therapy or surgery within one month prior to study entry.
Patients should have been off other investigational therapy for one month prior to receiving treatment on this study
TREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this study
Patients should have been off other investigational therapy for one month prior to entry in this study
Patients should have been off other investigational therapy for one month prior to receiving treatment on this study
INCLUSION - INFUSION: Patients should have been off other investigational therapy for 4 weeks prior to entry in this study
No other investigational anti-neoplastic therapy for one month prior to entry in this study
No other investigational anti-neoplastic therapy for one month prior to entry in this study
Patients should have been off other investigational therapy for one month prior to entry in this study
off other investigational therapy for one month prior to entry in this study.
No other investigational antitumor therapy for one month prior to entry in this study
Participation in any other research protocol involving administration of an investigational agent within 1 month prior to study entry
TREATMENT: Patients should have been off other investigational therapy for one month prior to entry in this study
Patients should have been off other investigational therapy for 4 weeks prior to entry in this study
Treatment with radiation therapy or surgery within one month prior to study entry
Prior investigational therapy must be completed at least 30 days prior to study entry
AT THE TIME OF INFUSION: Off investigational therapy for 4 weeks prior to study entry
Patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study
Investigational therapy less than one month prior to study entry
Patients should have been off other investigational therapy for one month prior to entry in this study